Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells

Haematologica

Volumn 95, Issue 6, 2010, Pages 1036-1037

  Janssen, Jeroen J W M ^a   Denkers, Fedor ^a   Valk, Peter ^b   Cornelissen, Jan J ^b   Schuurhuis, Gerrit Jan ^a   Ossenkoppele, Gert J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Blast crisis; Cml; Methylation

Indexed keywords

ALPHA INTERFERON; CADHERIN; CD34 ANTIGEN; CELL ADHESION MOLECULE; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYTARABINE; DNA BINDING PROTEIN; ESTROGEN RECEPTOR ALPHA; HYDROXYUREA; IDARUBICIN; IMATINIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN CDH13; PROTEIN IGSF4; PROTEIN MSH1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; BLAST CELL CRISIS; BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA ISOLATION; HUMAN; LETTER; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN METHYLATION; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; BLAST CRISIS; DNA METHYLATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED;

EID: 77953192489     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.015693     Document Type: Letter

References (11)

1. Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, et al. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005;33(14):e128.
2. Paulsson K, An Q, Moorman AV, Parker H, Molloy G, Davies T, et al. Methylation of tumour suppressor gene promoters in the presence and absence of transcriptional silencing in high hyperdiploid acute lymphoblastic leukaemia. Br J Haematol. 2009;144(6):838-847.
3. Henken FE, Wilting SM, Overmeer RM, van Rietschoten JG, Nygren AO, Errami A, et al. Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer. 2007;97(10):1457-1464.
4. Deutsch E, Jarrousse S, Buet D, Dugray A, Bonnet ML, Vozenin-Brotons MC, et al. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood. 2003;101(11):4583-4588.
5. Nguyen C, Liang G, Nguyen TT, Tsao-Wei D, Groshen S, Lübbert M, et al. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst. 2001;93(19):1465-1472.
6. iRoman-Gomez J, Castillejo JA, Jimenez A, Cervantes F, Boque C, Hermosin L, et al. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. J Clin Oncol. 2003;21(8):1472-1479.
7. Issa JP, Zehnbauer BA, Civin CI, Collector MI, Sharkis SJ, Davidson NE, et al. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res. 1996;56(5): 973-977.
8. Nguyen TT, Mohrbacher AF, Tsai YC, Groffen J, Heisterkamp N, Nichols PW, et al. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. Blood. 2000;95(9):2990-2992.
9. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, Sasaki H. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001;97(5):1172-1179.
10. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, et al. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003;98(3):522-528.
11. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'brien S, Verstovsek S, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007;109(5):899-906.